

SAFETY DATA SHEET



CRAYVALLAC® LA-150

1. PRODUCT AND COMPANY IDENTIFICATION

Company

Arkema Inc.
900 First Avenue
King of Prussia, Pennsylvania 19406

Arkema Coating Resins

Customer Service Telephone Number: (877) 331-6696
(Monday through Friday, 8:00 AM to 5:00 PM EST)

Emergency Information

Transportation: CHEMTREC: (800) 424-9300
(24 hrs., 7 days a week)
Medical: Rocky Mountain Poison Center: (866) 767-5089
(24 hrs., 7 days a week)

Product Information

Product name: CRAYVALLAC® LA-150
Synonyms: Not available
Molecular formula: Mixture
Chemical family: MODIFIED UREA SOLUTION
Product use: Additive for :Paint, Coatings, Inks, Adhesives

SECTION 2: HAZARDS IDENTIFICATION

Emergency Overview

Color: Colourless to yellow.
Physical state: liquid
Odor: sulphurous

*Classification of the substance or mixture:

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Not a hazardous substance or mixture.

GHS-Labeling

Not a hazardous substance or mixture.

Supplemental information:

Potential Health Effects:

Due to the presence of the solvent : Prolonged or repeated skin contact may cause defatting resulting in drying,

SAFETY DATA SHEET



CRAYVALLAC® LA-150

redness and rash. Can be absorbed through the skin.

May also cause: Strong garlic-like odor of the breath, fatigue, (severity of effects depends on extent of exposure).

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical name	CAS-No.	Wt/Wt	GHS Classification**
Proprietary modified urea	121121*	$\geq 30 - < 60 \%$	Not classified
Methane, sulfinylbis-	67-68-5	$\geq 30 - < 60 \%$	H227
Lithium chloride	7447-41-8	$\geq 1 - < 5 \%$	H303, H315, H320
Water	7732-18-5	$\geq 1 - < 5 \%$	Not classified

*The specific chemical identity is withheld because it is trade secret information of Arkema Inc.

**For the full text of the H-Statements mentioned in this Section, see Section 16.

SECTION 4: FIRST AID MEASURES**4.1. Description of necessary first-aid measures:****Inhalation:**

If inhaled, remove victim to fresh air.

Skin:

In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse.

Eyes:

Immediately flush eye(s) with plenty of water.

Ingestion:

If swallowed, DO NOT induce vomiting. Get medical attention. Never give anything by mouth to an unconscious person.

SAFETY DATA SHEET



CRAYVALLAC® LA-150

4.2. Most important symptoms and effects, both acute and delayed:

For most important symptoms and effects (acute and delayed), see Section 2 (Hazard Statements and Supplemental Information if applicable) and Section 11 (Toxicology Information) of this SDS.

4.3. Indication of any immediate medical attention and special treatment needed:

Unless otherwise noted in Notes to Physician, no specific treatment noted; treat symptomatically.

SECTION 5: FIREFIGHTING MEASURES

Extinguishing media (suitable):

Water spray, Carbon dioxide (CO₂), Foam, Dry chemical

Protective equipment:

Fire fighters and others who may be exposed to products of combustion should wear full fire fighting turn out gear (full Bunker Gear) and self-contained breathing apparatus (pressure demand / NIOSH approved or equivalent).

Further firefighting advice:

Fire fighting equipment should be thoroughly decontaminated after use.

Fire and explosion hazards:

When burned, the following hazardous products of combustion can occur:

Carbon oxides
Sulphur oxides
Nitrogen oxides
Cyanides
hydrogen sulfide
Hazardous organic compounds

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions, Emergency procedures, Methods and materials for containment/clean-up:

Prevent further leakage or spillage if you can do so without risk. Ventilate the area. Avoid generation of vapors. Contain and collect spillage with non-combustible absorbent material such as clean sand, earth, diatomaceous earth or non-acidic clay and place into suitable properly labeled containers for prompt disposal. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits.

Protective equipment:

Appropriate personal protective equipment is set forth in Section 8.

CRAYVALLAC® LA-150

SECTION 7: HANDLING AND STORAGE**Handling****General information on handling:**

Avoid breathing vapor or mist.

Handle in accordance with good industrial hygiene and safety practices. These practices include avoiding unnecessary exposure and removal of material from eyes, skin, and clothing.

Storage**General information on storage conditions:**

This material is not hazardous under normal storage conditions; however, material should be stored in closed containers, in a secure area to prevent container damage and subsequent spillage.

Storage stability – Remarks:

Stable under recommended storage conditions.

Storage incompatibility – General:

Store separate from:

Organic and mineral acids (sulphur, phosphorus) halides

Methylbromide

Sodium hydride

Zinc, Steel (in the presence of water)

Strong acids

Strong oxidizing agents

Temperature tolerance – Do not store below:

68 °F (20 °C)

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**Airborne Exposure Guidelines:****Methane, sulfinylbis- (67-68-5)**

US. OARS. WEELs Workplace Environmental Exposure Level Guide, as amended

Time weighted average	250 ppm
-----------------------	---------

Remarks:	Listed
----------	--------

Only those components with exposure limits are printed in this section. Limits with skin contact designation above have skin contact effect. Air sampling alone is insufficient to accurately quantitate exposure. Measures to prevent significant cutaneous absorption may be required. Limits with a sensitizer designation above mean that exposure to this material may cause allergic reactions.

Engineering controls:

SAFETY DATA SHEET



CRAYVALLAC® LA-150

Investigate engineering techniques to reduce exposures below airborne exposure limits or to otherwise reduce exposures. Provide ventilation if necessary to minimize exposures or to control exposure levels to below airborne exposure limits (if applicable see above). If practical, use local mechanical exhaust ventilation at sources of air contamination such as open process equipment.

Respiratory protection:

Avoid breathing vapor or mist. Where airborne exposure is likely or airborne exposure limits are exceeded (if applicable, see above), use NIOSH approved respiratory protection equipment appropriate to the material and/or its components. Consult respirator manufacturer to determine appropriate type equipment for a given application. Observe respirator use limitations specified by NIOSH or the manufacturer. For emergency and other conditions where there may be a potential for significant exposure or where exposure limit may be significantly exceeded, use an approved full face positive-pressure, self-contained breathing apparatus or positive-pressure airline with auxiliary self-contained air supply. Respiratory protection programs must comply with 29 CFR § 1910.134.

Skin protection:

Minimize skin contamination by following good industrial hygiene practice. Wearing protective gloves is recommended. Wash hands and contaminated skin thoroughly after handling.

Eye protection:

Use good industrial practice to avoid eye contact.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Color:	Colourless to yellow.
Physical state:	liquid
Odor:	sulphurous
Odor threshold:	No data available
Flash point	> 203 °F (> 95 °C) (Method: Seta Flash Method)
Lower flammable limit (LFL):	No data available
Upper flammable limit (UFL):	No data available
pH:	Not applicable
Density:	1.1 g/cm ³ (68 °F (20 °C))
Specific Gravity (Relative density):	1.1 (68 °F (20 °C))Water=1 (liquid)
Vapor pressure:	0.417 mmHg (68 °F (20 °C))
Boiling point/boiling range:	372 °F (189 °C)

CRAYVALLAC® LA-150

Melting point/range:	65.3 °F (18.5 °C)
Freezing point:	No data available.
Evaporation rate:	No data available
Solubility in water:	insoluble
Viscosity, dynamic:	No data available
Oil/water partition coefficient:	(No data available)
Thermal decomposition:	No data available
Flammability:	See GHS Classification in Section 2 if applicable

SECTION 10: STABILITY AND REACTIVITY**Stability:**

Hygroscopic product (strongly) Stability of the solution decreases under the action of heat, light, and in the presence of impurities

Hazardous reactions:

Hazardous polymerization does not occur.

Materials to avoid:

Organic and mineral acids (sulphur, phosphorus) halides
Methylbromide
Sodium hydride
Zinc, Steel (in the presence of water)
Strong acids
Strong oxidizing agents

Conditions / hazards to avoid:

Keep away from heat and sources of ignition. To avoid thermal decomposition, do not overheat.

Hazardous decomposition products:

Thermal decomposition giving flammable and toxic products :
Carbon oxides
Sulphur oxides
Nitrogen oxides
Cyanides
Hydrogen sulphide
Hazardous organic compounds
Formaldehyde
Methylmercaptan
Dimethylsulphide

CRAYVALLAC® LA-150

Product of hydrolysis :
Dimethyl sulfone

SECTION 11: TOXICOLOGICAL INFORMATION

Data on this material and/or its components are summarized below.

Data for CRAYVALLAC® LA-150**Acute toxicity****Oral:**

Practically nontoxic. Acute toxicity estimate > 5,000 mg/kg.

Data for Methane, sulfinylbis- (67-68-5)**Acute toxicity****Oral:**

Practically nontoxic. (rat) LD50 = 28,300 mg/kg.

Dermal:

Practically nontoxic. (rat) LD50 = 40,000 mg/kg.

Inhalation:

No deaths occurred. (rat) 4 h LC0 > 5.33 mg/l. (dust/mist)

Skin Irritation:

Practically non-irritating. (rabbit) (4 h)

Eye Irritation:

Causes mild eye irritation. (rabbit)

Skin Sensitization:

Not a sensitizer. Guinea pig maximization test. No skin allergy was observed

Not a sensitizer. LLNA: Local Lymph Node Assay. (mouse) No skin allergy was observed

Repeated dose toxicity

Chronic oral administration to monkey / signs: At high dose :, Sweating, Vomiting

Chronic oral administration to rat, dog / affected organ(s): eye / signs: changes in organ structure or function / (Repeated exposure at high concentrations)

Subchronic inhalation administration to rat / signs: Local irritation / No adverse systemic effects reported.

Chronic dermal administration to monkey / signs: Local irritation / No adverse systemic effects reported.

Subchronic dermal administration to dog / affected organ(s): eye / signs: changes in organ structure or

CRAYVALLAC® LA-150

function / (Repeated exposure at high concentrations)

Subchronic dermal administration to rabbit / affected organ(s): eye / signs: changes in organ structure or function / (Repeated exposure at high concentrations)

Genotoxicity**Assessment in Vitro:**

No genetic changes were observed in laboratory tests using: bacteria, animal cells, yeast

Genotoxicity**Assessment in Vivo:**

No genetic changes were observed in laboratory tests using: rats, mice, fruit flies

Developmental toxicity

Exposure during pregnancy. Oral (rat, rabbit) / No birth defects were observed.

Reproductive effects

Reproductive/Developmental Effects Screening Assay. Oral (rat) / No toxicity to reproduction.

Human experience**General:**

Rapidly absorbed through skin.

Human experience**Skin contact:**

Skin: dry skin, dermatitis, rash, redness. (repeated or prolonged exposure)

Systemic effects: Strong garlic-like odor of the breath, headache, eye pain, fatigue, dizziness.

Skin: No skin allergy was observed.

Human experience**Eye contact:**

Eyes: stinging, tearing.

Data for Lithium chloride (7447-41-8)**Acute toxicity****Oral:**

Harmful if swallowed. (rat) LD50 = 526 mg/kg.

Dermal:

No deaths occurred. (rat) LD0 = 2,000 mg/kg.

Inhalation:

Practically nontoxic. (rat) 4 h LC50 > 5.57 mg/l. (dust/mist)

Skin Irritation:

CRAYVALLAC® LA-150

Causes skin irritation. (rabbit) (4 h)

Eye Irritation:

Causes eye irritation. (rabbit)

Skin Sensitization:

Not a sensitizer. Buehler method. (guinea pig) No skin allergy was observed.

Repeated dose toxicity

Repeated dietary administration to rat / affected organ(s): Thyroid gland, reproductive system / signs: atrophy, changes in body weight, decreased growth rate / Repeated exposure at high concentrations

Chronic drinking water administration to rat / signs: At high concentrations, tremors, loss of muscle coordination, decreased growth rate, death

Chronic oral administration to dog / affected organ(s): kidney

Genotoxicity**Assessment in Vitro:**

No genetic changes were observed in laboratory tests using: bacteria, human cells, animal cells, (data for a similar material)

Developmental toxicity

Exposure during pregnancy. drinking water (rat) / No birth defects were observed.

Exposure during pregnancy. oral (rat) / No birth defects were observed. (at doses that produce effects in mothers, data for a similar material)

Reproductive effects

Two-generation study. Oral (rat) / No toxicity to reproduction. / (data for a similar material)

SECTION 12: ECOLOGICAL INFORMATION**Chemical Fate and Pathway**

Data on this material and/or its components are summarized below.

Data for CRAYVALLAC® LA-150**Octanol Water Partition Coefficient:**

(No data available)

Data for Proprietary modified urea (Proprietary)**Octanol Water Partition Coefficient:**

log Pow: = 2.4 - 3.1

Data for Methane, sulfinylbis- (67-68-5)**Biodegradation:**

Not readily biodegradable. (28 d) biodegradation 31 %

CRAYVALLAC® LA-150

Octanol Water Partition Coefficient:

log Pow: = -1.35, at 68 °F (20 °C)

Data for Lithium chloride (7447-41-8)**Octanol Water Partition Coefficient:**

log Pow: = -0.4668 °F (20 °C) (Method: calculated)

Ecotoxicology

Data on this material and/or its components are summarized below.

Data for Methane, sulfinylbis- (67-68-5)**Aquatic toxicity data:**

Practically nontoxic. Danio rerio (zebra fish) 96 h LC50 > 25,000 mg/l

Aquatic invertebrates:

Practically nontoxic. Daphnia magna (Water flea) 48 h EC50 = 24,600 mg/l

Algae:

Practically nontoxic. Pseudokirchneriella subcapitata (microalgae) 72 h ErC50 = 17,000 mg/l

Microorganisms:

Respiration inhibition / Activated sludge 30 min EC50 = 10 - 100 mg/l

Cell multiplication inhibition test / Pseudomonas putida 16 h EC50 = 16,000 mg/l

Data for Lithium chloride (7447-41-8)**Aquatic toxicity data:**

Practically nontoxic. Oncorhynchus mykiss 96 h LC50 = 158 mg/l

Aquatic invertebrates:

Practically nontoxic. Daphnia magna (Water flea) 48 h EC50 249 mg/l

Algae:

Practically nontoxic. Raphidocelis subcapitata (freshwater green algae) 72 h EC50 (Growth inhibition) > 400 mg/l

Microorganisms:

Respiration inhibition / Activated sludge 3 h EC50 = 320 mg/l (similar material)

Chronic toxicity to fish:

Practically nontoxic. Danio rerio (zebra fish) 34 d NOEC = 18 mg/l

Chronic toxicity to aquatic invertebrates:

Practically nontoxic. Daphnia magna (Water flea) 21 d NOEC = 1.7 mg/l (data for a similar material)

Chronic toxicity to aquatic plants:Practically nontoxic. Desmodesmus subspicatus (green algae) 72 h NOEC = 10 mg/l

CRAYVALLAC® LA-150

SECTION 13: DISPOSAL CONSIDERATIONS**Waste disposal:**

Where possible recycling is preferred to disposal or incineration. If recycling is not an option, incinerate or dispose of in accordance with federal, state, and local regulations. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits. Note: Chemical additions to, processing of, or otherwise altering this material may make this waste management information incomplete, inaccurate, or otherwise inappropriate. Furthermore, state and local waste disposal requirements may be more restrictive or otherwise different from federal laws and regulations.

SECTION 14: TRANSPORT INFORMATION

US Department of Transportation (DOT): not regulated

International Maritime Dangerous Goods Code (IMDG): not regulated

SECTION 15: REGULATORY INFORMATION**Chemical Inventory Status**

US. Toxic Substances Control Act	TSCA	The components of this product are all on the Active TSCA Inventory.
Canadian Domestic Substances List (DSL)	DSL	This product contains one or several components that are not on the Canadian DSL nor NDSL lists.
China. Inventory of Existing Chemical Substances in China (IECSC)	IECSC (CN)	This product contains at least one component covered by an exemption/registration. Please consult Arkema for more information.
Japan. ENCS - Existing and New Chemical Substances Inventory	ENCS (JP)	All components of this product are listed or exempted
Japan. ISHL - Inventory of Chemical Substances	ISHL (JP)	All components of this product are listed or exempted
Korea. Korean Existing Chemicals Inventory (KECI)	KECI (KR)	Not all components of this product are listed or exempted
Philippines Inventory of Chemicals and Chemical Substances (PICCS)	PICCS (PH)	The mixture contains a polymer. All the monomers for this polymer & other substances are listed on the inventory, Consult Arkema.

SAFETY DATA SHEET



CRAYVALLAC® LA-150

Australian Inventory of Industrial Chemicals	AU AIICL	This product contains at least one component covered by an exemption/registration. Please consult Arkema for more information.
Taiwan Chemical Substance Inventory (TCSI)	TCSI	Not all components of this product are listed or exempted

United States – Federal Regulations**SARA Title III – Section 302 Extremely Hazardous Chemicals:**

The components in this product are either not SARA Section 302 regulated or regulated but present in negligible concentrations.

SARA Title III - Section 311/312 Hazard Categories:

No SARA Hazards

SARA Title III – Section 313 Toxic Chemicals:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) - Reportable Quantity (RQ):

The components in this product are either not CERCLA regulated, regulated but present in negligible concentrations, or regulated with no assigned reportable quantity.

United States – State Regulations**California Prop. 65**

WARNING! This product contains a chemical known to the State of California to cause cancer.

Chemical name	CAS-No.
Benzene, 2,4-diisocyanato-1-methyl-	584-84-9
Benzene, 1,3-diisocyanato-2-methyl-	91-08-7

SECTION 16: OTHER INFORMATION**Full text of H-Statements referred to under sections 2 and 3.**

H227	Combustible liquid.
H303	May be harmful if swallowed.
H315	Causes skin irritation.
H320	Causes eye irritation.

Latest Revision(s):

Reference number:	200002945
Date of Revision:	03/10/2025

SAFETY DATA SHEET



CRAYVALLAC® LA-150

Date Printed: 03/10/2025

CRAYVALLAC® is a registered trademark of Arkema Inc.

All information contained herein is believed to be accurate as of the date of publication, is provided "as-is" and is subject to change without notice. This is not a warranty, an agreement, or substitute for expert or professional advice. Arkema Inc. ("Company") expressly disclaims and assumes no liability for the use of the products or reliance on this information. It is the sole responsibility of the user to determine the suitability of any products for user's application(s). NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED (INCLUDING SUITABILITY FOR USE IN ANY MEDICAL DEVICE OR MEDICAL APPLICATION), IS MADE CONCERNING THE PRODUCTS OR THE INFORMATION PROVIDED HEREIN. The information provided relates only to the specific products designated herein and may not be valid where such products are used in combination with other materials or in any process. The performance of the product, its shelf life, and application characteristics depends on many variables, and changes in these variables can impact product performance. You are responsible to test the suitability of any product in advance for any intended use or application and before commercialization. Nothing herein shall be construed as a license for the use of any product in a manner that might infringe any patent and it should not be construed as an inducement to infringe any patent. Please carefully review the Safety Data Sheet for the product.

The Company adheres to a strict policy that applies to the use of any of its products in medical device applications. This policy can be found at <https://www.arkema.com/global/en/social-responsibility/innovation-and-sustainable-solutions/responsible-product-management/medical-device-policy/> which is incorporated herein by reference and made a part hereof. Except as expressly authorized, the Company (i) has designated specific medical grade compositions for products used in medical device applications and Company products not so designated are not authorized for use in medical device applications and (ii) strictly prohibits the use of any of its products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Company does not design, manufacture and/or directly sell any medical devices. The Company does not co-design, or offer assistance to any purchaser of its products, in their design, manufacture and/or sale of products for medical devices. It is the sole responsibility of the manufacturer of medical devices to determine the suitability of all raw material, products and components, including any medical grade products, in order to ensure that the medical device is safe for end-use and complies with all applicable legal and regulatory requirements and to conduct all necessary tests and inspections.